Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q4 2020 · 10-K
Revenue$44.05M$44.05M+24.3% vs Q4 2019 Net Income-$97.66M-$97.66MderivedN/M vs Q4 2019 EPS Diluted-$1.41-$1.41N/M vs Q4 2019 Operating Income-$92,434,000
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
N/M
Operating Cash Flowderived-$49,397,000N/M Free Cash Flowderived-$50,414,000N/M Margins · derivedOperating margin-209.9%+89.0 pt vs Q4 2019
Net margin-221.7%+67.1 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 25, 2021 · 56 d after period end